SAHPRA Statement – Update on Sisonke Phase 3B Implementation Study
17 April 2021 SAHPRA has engaged with the Sisonke Phase 3B Implementation Study ...
17 April 2021 SAHPRA has engaged with the Sisonke Phase 3B Implementation Study ...
13 April 2021 We have noted the decision taken by the Food and Drug Administrati...
9 April 2021 On 6 April 2021 the Pretoria High Court issued a court order pertai...
01 April 2021 The South African Health Products Authority (SAHPRA) registered th...
29 March 2021 The SABC placed an erroneous report that “SAHPRA has agreed to all...
25 March 2021 As the entire world ushered in 2020, no one had any idea how life,...
19 March 2021 SAHPRA has implemented a new and improved online submission portal...
19 March 2021 On 16 March 2021 SAHPRA registered Soolantra 10mg/g cream formulat...
16 March 2021 SAHPRA has approved the Section 21 application for the Pfize...
03 February 2021 There is an erroneous notion that SAHPRA “buckled under pressur...
27 January 2021 In an effort to enable and support the country’s response in fig...
06 January 2021 SAHPRA is pleased to announce the commencement of the build of a...
22 December 2020 Post Importation Testing Exemptions (PITE) granted due to COVID...
19 December 2020 Health Minister Dr Zweli Mkhize on Friday announced that a vari...
10 December 2020 What is a Covid-19 Vaccine? A COVID‑19 vaccine is any of severa...
04 December 2020 Coronavirus disease (COVID-19) is an infectious disease caused ...
19 November 2020 The Backlog Clearance Team has been made aware of a miscommunic...
SAHPRA has implemented an application status checker. This new tool is listed un...
Embargo: Immediate release SAHPRA has issued Section 21 authorisation for one se...
In the interest of public health, SAHPRA has launched the COVI-Vig reporting sys...